Holen Sie sich die Stockscreener-App
67.35
3.76%
-2.63
Handel nachbörslich:
67.35
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$69.98
Offen:
$70.96
24-Stunden-Volumen:
4.29M
Relative Volume:
0.78
Marktkapitalisierung:
$25.99B
Einnahmen:
$4.82B
Nettoeinkommen (Verlust:
$930.40M
KGV:
28.81
EPS:
2.3381
Netto-Cashflow:
$1.43B
1W Leistung:
-2.28%
1M Leistung:
-8.67%
6M Leistung:
+1.48%
1J Leistung:
-22.84%
1-Tages-Spanne:
$67.30
$70.96
1-Wochen-Bereich:
$67.30
$71.08
52-Wochen-Spanne:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
67.35 | 27.07B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
90.74 | 163.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
314.84 | 127.55B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.23 | 103.66B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
42.68 | 65.74B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.46 | 52.27B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Eingeleitet | Evercore ISI | In-line |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
Devon Energy Wolfcamp development programshale wells drive long-term output - AD HOC NEWS
Is DexCom Inc (DXCM) a Bargain After 3.8% Drop? GF Value Says Un - GuruFocus
Dexcom G7 Professional from Dexcom Inc.Clinic-first CGM for short-term wear - AD HOC NEWS
DXCM ALERT: Securities Fraud Class Action Launched Against DexCom, Inc.December 26, 2025 Deadline - The National Law Review
Enterprise value to EBITDA forward of DexCom, Inc. – SIX:DXCM - TradingView
Price to sales forward of DexCom, Inc. – SIX:DXCM - TradingView
Price to book forward of DexCom, Inc. – NASDAQ:DXCM - TradingView
Redefining CGM for people with type 2 diabetes: Dexcom announces Dexcom Flex in Germany - MSN
Price to earnings forward of DexCom, Inc. – SIX:DXCM - TradingView
Devon Energy expands Permian drilling plan, shares tied to oil price swings - AD HOC NEWS
Dexcom Inc. extends Stelo reach, shares in focus on NASDAQ - AD HOC NEWS
DexCom Continues Push Towards Universal Glucose Biosensing with Latest AdvancesEarnings Risk Report - dars.gov.et
DexCom, Inc. (DXCM) Further Advances Vision of Glucose Biosensing for All - Insider Monkey
Did You Lose Money on DexCom, Inc. (DXCM)? Levi & Korsinsky Urges Investors to Act Before December 26, 2025 - The National Law Review
Join Class Action to Recover Losses from DexCom, Inc. (DXCM)Contact Levi & Korsinsky Before December 26, 2025 - The National Law Review
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. InvestorsLead Plaintiff Deadline December 26, 2025 - The National Law Review
Recover Investment Losses: Class Action Initiated Against DexCom, Inc. (DXCM) - The National Law Review
Deutsche Bank Names Top Healthcare Stocks Led by DexCom and Insulet - Investing.com Canada
Dexcom G7 from Dexcom Inc.smaller sensor, quicker warm-up and app-first thinking - Ad-hoc-news.de
The STACK oil gathering system from Devon Energy Corp.quietly critical for getting barrels to mar - Ad-hoc-news.de
DexCom (DXCM) Stock After Three-Year 45% Slide Is The Market Too Pessimistic - Yahoo Finance
Abbott's Dual-Analyte Bet Positions It to Outpace Dexcom in the Expanding CGM Market - Kavout | AI
Dexcom Inc launches redesigned Stelo app, shares trade around key Nasdaq level - Ad-hoc-news.de
DexCom, Inc. Actuals & Estimates (NASDAQ:DXCM) - TradingView
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Devon Energy consensus steady, shares track U.S. oil peers - Ad-hoc-news.de
DexCom, Inc. Actuals & Estimates (HAN:DC4) - TradingView
Dexcom reports clear analyst support, shares trade below new Deutsche Bank target - Ad-hoc-news.de
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now? - Yahoo Finance
Dexcom Inc (DXCM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dexcom Inc (DXCM) Institutional Confidence - TradingKey
DexCom (DXCM) Launches New Stelo App As It Expands Into Four Countries - Sahm
Dexcom Inc (DXCM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
DexCom, Inc. Actuals & Estimates (FWB:DC4) - TradingView
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
DexCom Inc. (NASDAQ:DXCM): Why Healthcare Is Watching? - Kalkine Media
DexCom, Inc. Actuals & Estimates (SIX:DXCM.USD) - TradingView
DXCM Forecast — Price Target — Prediction for 2027 - TradingView
Dexcom alerts users after stolen G7 sensors allegedly sold by unauthorized distributor - Class Action Lawsuits
DexCom to Roll Out Reimagined Stelo App With Global Expansion Plans - The Globe and Mail
Dexcom - Forbes
Dexcom Inc (DXCM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Why DexCom (DXCM) Is Down 6.9% After FDA Clears Stelo OTC CGM For Young Children - Sahm
DexCom’s quarterly earnings preview: What you need to know - MSN
DexCom (DXCM) Advances Glucose Monitoring Accessibility - GuruFocus
Dexcom Further Advances Vision of Glucose Biosensing for All, shares under fresh Deutsche Bank cover - Ad-hoc-news.de
Benchmark reiterates Dexcom stock rating on new sensor launch By Investing.com - Investing.com South Africa
Deutsche Bank initiates DexCom stock with buy rating on CGM growth - Investing.com UK
Deutsche Bank initiates DexCom stock with buy rating on CGM growth By Investing.com - Investing.com Australia
DexCom, Insulet gain news Buys at Deutsche Bank despite recent selloff - Seeking Alpha
Dexcom Further Advances Vision of Glucose Biosensing for All - GuruFocus
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):